cumberland-rhode-island
(2)
Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals is a Cumberland, Rhode Island biotechnology company that develops long-acting therapies for chronic retinal diseases using its Encapsulated Cell Technology (ECT) platform - a tiny implant of genetically engineered cells that continuously secretes a therapeutic protein inside the eye. In March 2025 its lead product ENCELTO (revakinagene taroretcel-lwey, formerly NT-501/Renexus) became the first and only FDA-approved treatment for macular telangiectasia type 2 (MacTel), delivering ciliary neurotrophic factor (CNTF) to slow the loss of photoreceptors.
Rich Small
Rich Small is the CEO of Neurotech Pharmaceuticals, the Cumberland, Rhode Island clinical-stage biotech that in March 2025 won FDA approval for ENCELTO, the first and only treatment for macular telangiectasia type 2 (MacTel). A CPA and Northeastern University graduate, he joined Neurotech as CFO in 2007 and took over the top job in 2016, guiding the company's encapsulated cell technology platform from experimental science to a commercial retinal implant.